Latest news with #NMOSD
Globe and Mail
2 days ago
- Health
- Globe and Mail
Neuromyelitis Optica Spectrum Disorder Market Poised for Transformation with New Disease-Modifying Therapies and Regulatory Approvals
DelveInsight projects strong NMOSD market growth in the 7MM through 2032, fueled by disease-modifying therapies and key approvals. Leading NMOSD companies include RemeGen, Alexion, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, and NovelMed, advancing novel mechanisms such as complement inhibition and B-cell depletion. DelveInsight's ' Neuromyelitis Optica Spectrum Disorder Market Insight, Epidemiology And Market Forecast - 2032 ' report delivers a comprehensive analysis of the GnRH Receptor Antagonist market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of Neuromyelitis Optica Spectrum Disorder in the 7MM is expected to surge significantly by 2032, with comprehensive coverage across the United States, EU4 countries (Germany, Spain, Italy, and France), the United Kingdom, and Japan during the forecast period from 2024-2032. Patient population data: The report provides the total Neuromyelitis Optica Spectrum Disorder potential patient pool with detailed epidemiology segmentation across all seven major markets, including historical patient data from 2019 and forecasted trends through 2032, encompassing diagnosed patient pools and treatment-eligible populations. Key companies: Leading Neuromyelitis Optica Spectrum Disorder companies such as RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, and others are actively developing innovative therapeutic solutions. Pipeline assets: The comprehensive pipeline analysis covers emerging therapies across Phase II and Phase III development stages, with detailed therapeutic candidate profiles representing diverse mechanisms of action and novel approaches to address current treatment limitations. In April 2025, UPLIZNA® (inebilizumab-cdon) received FDA approval for Immunoglobulin G4-related disease. It represents the continued expansion of this therapy that was originally approved for AQP4-IgG+ NMOSD patients. Discover recent advancements in the Neuromyelitis Optica Spectrum Disorder treatment landscape @ Neuromyelitis Optica Spectrum Disorder Recent Developments. Neuromyelitis Optica Spectrum Disorder Market Dynamics The Neuromyelitis Optica Spectrum Disorder market represents an evolving therapeutic landscape characterized by significant unmet medical needs and emerging treatment paradigms. The current market reflects a critical juncture where traditional treatment approaches are being supplemented by innovative therapeutic strategies targeting specific disease mechanisms. The Neuromyelitis Optica Spectrum Disorder market drivers include increased disease awareness, improved diagnostic capabilities, and growing recognition of NMOSD as a distinct clinical entity requiring specialized treatment approaches. The market's evolution is fundamentally supported by advancing scientific understanding of NMOSD pathophysiology, particularly the role of aquaporin-4 antibodies and complement-mediated inflammatory processes. This enhanced mechanistic insight has enabled the development of targeted therapeutic interventions that address underlying disease mechanisms rather than merely managing symptoms. The therapeutic rationale for emerging treatments centers on complement inhibition, B-cell depletion, and immunomodulatory approaches designed to prevent relapse occurrence and minimize neurological disability progression. The neuromyelitis optica spectrum disorder market clinical development activity demonstrates robust industry engagement, with multiple therapeutic candidates progressing through Phase II and Phase III trials. The pipeline reflects diverse therapeutic approaches, including monoclonal antibodies, small molecules, and biologics targeting different aspects of NMOSD pathogenesis. This diversified development strategy indicates industry confidence in market potential and commitment to addressing varied patient needs across different disease stages and phenotypes. The neuromyelitis optica spectrum disorder competitive landscape reveals significant pharmaceutical industry participation, with established biotechnology companies and emerging biotech firms pursuing complementary development strategies. Strategic collaborations between industry partners and academic institutions are accelerating research progress and enabling risk-sharing arrangements that support continued investment in this rare disease area. Market positioning strategies emphasize differentiation through mechanism of action, safety profiles, and administration convenience. Current Neuromyelitis Optica Spectrum Disorder market barriers include the rarity of NMOSD, which complicates clinical trial design and patient recruitment, while regulatory pathways for rare diseases present both opportunities through expedited review processes and challenges related to evidence generation requirements. Market opportunities are substantial, given the high unmet medical need, potential for premium pricing in rare disease segments, and expanding global awareness leading to improved diagnosis rates. The future neuromyelitis optica spectrum disorder market outlook indicates sustained growth driven by pipeline maturation, regulatory approvals, and expanding treatment accessibility. Market expectations center on the introduction of disease-modifying therapies that can fundamentally alter NMOSD disease trajectory, representing a paradigm shift from current symptomatic management approaches toward comprehensive disease control. Download the Neuromyelitis Optica Spectrum Disorder Market report to understand which factors are driving the therapeutic market @ Neuromyelitis Optica Spectrum Disorder Market Trends. Neuromyelitis Optica Spectrum Disorder Epidemiology The Neuromyelitis Optica Spectrum Disorder epidemiology across the seven major markets reveals significant geographic and demographic variations that influence market dynamics and therapeutic development strategies. The comprehensive epidemiological analysis encompasses the United States, EU5 countries, including Germany, France, Italy, Spain, and the United Kingdom, plus Japan, representing the most significant commercial markets for NMOSD therapeutics. Historical epidemiology data spanning from 2019 provides a baseline understanding of neuromyelitis optica spectrum disorder prevalence patterns, while forecasted trends through 2032 illuminate evolving patient population dynamics driven by improved diagnostic awareness and refined clinical criteria. The neuromyelitis optica spectrum disorder epidemiology segmentation within the report addresses multiple patient population categories, including total diagnosed cases, treatment-eligible patients, and those receiving current therapeutic interventions. This segmentation approach enables precise market sizing and facilitates targeted therapeutic development strategies. The analysis reveals geographic variations in NMOSD prevalence, with certain regions demonstrating higher disease burden potentially related to genetic predisposition, environmental factors, or diagnostic accessibility differences. Total treated cases encompass patients currently receiving therapeutic interventions, ranging from immunosuppressive therapies to symptomatic management approaches. This metric provides insight into current treatment penetration and identifies opportunities for therapeutic improvement and market expansion. Geographic segmentation across the 7MM breakdown reveals market-specific opportunities and challenges, with developed markets typically demonstrating higher diagnostic rates and treatment accessibility compared to emerging regions. The forecast period through 2032 anticipates continued growth in diagnosed patient populations, driven by enhanced physician awareness, improved diagnostic technologies, and expanding healthcare infrastructure accessibility. Discover evolving trends in the Neuromyelitis Optica Spectrum Disorder patient pool forecasts @ Neuromyelitis Optica Spectrum Disorder Epidemiology Analysis. Key Neuromyelitis Optica Spectrum Disorder Companies and Treatment Market The clinical and regulatory landscape for Neuromyelitis Optica Spectrum Disorder reflects a dynamic environment where traditional treatment approaches are being transformed by innovative therapeutic strategies. Current treatment options primarily consist of immunosuppressive therapies and corticosteroids for acute management, along with off-label use of various immunomodulatory agents for relapse prevention. However, these conventional approaches often provide inadequate disease control and carry significant long-term safety concerns, creating substantial opportunities for targeted therapeutic interventions. Key neuromyelitis optica spectrum disorder companies include RemeGen with their complement inhibition platform, Alexion Pharmaceuticals leveraging their expertise in complement-mediated disorders, Reistone Biopharma developing innovative immunomodulatory approaches, and Nihon Pharmaceutical pursuing region-specific therapeutic strategies. Additional significant contributors include Harbour BioMed with their biologics platform, Bio-Thera Solutions focusing on biosimilar and novel therapeutic development, and Abide Therapeutics targeting specific enzymatic pathways. The landscape also features Bionure's neuroprotective approaches, TG Therapeutics' immunomodulatory strategies, ENDECE's innovative therapeutic platforms, Boston Pharmaceuticals' targeted interventions, and NovelMed's comprehensive development programs. Neuromyelitis Optica Spectrum Disorder market positioning strategies reflect the critical importance of demonstrating superior efficacy compared to current standard-of-care approaches while maintaining acceptable safety profiles. Companies are emphasizing mechanism-of-action differentiation, with some focusing on preventing relapse occurrence, others targeting neurological recovery, and several pursuing comprehensive approaches addressing both inflammatory control and neuroprotection. Neuromyelitis Optica Spectrum Disorder drug profiles within the pipeline demonstrate diverse therapeutic rationales, ranging from complement cascade inhibition to selective immune cell targeting. Development status varies across the portfolio, with some candidates approaching regulatory submission while others are in early clinical evaluation phases. Clinical applications span acute treatment settings, maintenance therapy for relapse prevention, and combination approaches designed to optimize long-term outcomes. Recent Neuromyelitis Optica Spectrum Disorder development milestones include advancing clinical trials, regulatory designations such as orphan drug status and fast-track designations, and strategic partnerships enabling accelerated development timelines. Commercial arrangements reflect the collaborative nature of rare disease development, with licensing deals and strategic collaborations enabling resource sharing and risk distribution across multiple development programs. Discover which companies are innovating in the Neuromyelitis Optica Spectrum Disorder treatment landscape @ Neuromyelitis Optica Spectrum Disorder Competitive Landscape. Conclusion The Neuromyelitis Optica Spectrum Disorder market represents a compelling therapeutic opportunity characterized by significant unmet medical needs, robust pipeline development, and expanding patient identification. DelveInsight's comprehensive analysis reveals a market poised for substantial transformation through 2032, driven by innovative therapeutic approaches, enhanced disease understanding, and growing clinical awareness. The convergence of scientific advancement, industry investment, and regulatory support creates an environment conducive to therapeutic breakthroughs that could fundamentally alter NMOSD treatment paradigms and significantly improve patient outcomes across the seven major global markets. Table of Contents 1. Key Insights 2. Executive Summary of Neuromyelitis Optica Spectrum Disorder 3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder 4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance 5. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview 6. Neuromyelitis Optica Spectrum Disorder Patient Journey 7. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Neuromyelitis Optica Spectrum Disorder Unmet Needs 10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment 11. Neuromyelitis Optica Spectrum Disorder Marketed Products 12. Neuromyelitis Optica Spectrum Disorder Emerging Therapies 13. Neuromyelitis Optica Spectrum Disorder: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder 17. KOL Views 18. Neuromyelitis Optica Spectrum Disorder Market Drivers 19. Neuromyelitis Optica Spectrum Disorder Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Cision Canada
07-08-2025
- Health
- Cision Canada
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG) Français
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) and adult patients with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG). With the agreement in place with the pCPA, individual provinces and territories may now initiate the process to list Ultomiris on their formularies, the timing of which will vary by province and territory. NMOSD is a rare and debilitating autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves. 1-4 Most people living with NMOSD experience unpredictable relapses, characterised by a new onset of neurologic symptoms or worsening of existing neurologic symptoms, which tend to be severe and recurrent and may result in permanent disability. 4,5 gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness. 6 Those living with gMG may initially experience slurred speech, double vision, droopy eyelids and weakness, with symptoms becoming more severe as the disease progresses, including extreme fatigue, difficulty swallowing, choking and respiratory failure. 7-8 "NMOSD is a rare neurological disease characterized by severe relapses that have significant impact on patients' lives. In the pivotal trial for Ultomiris (ravulizumab), all Ultomiris -treated patients remained adjudicated relapse free at Week 72. This was achieved with a much-improved delivery regimen every 2 months compared to Soliris (eculizumab) that is dosed every 2 weeks. This agreement with the pCPA is a huge step forward to providing patients access to this treatment and improving treatment of NMOSD in Canada," said Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), The Ottawa Hospital. "Ensuring NMOSD patients have access to therapies proven highly effective is a top priority for The Sumaira Foundation globally. Since establishing TSF Canada in 2021, we have been supporting efforts to make these therapies available to Canadian patients as well. We are therefore very pleased to hear the news that ravulizumab is now becoming accessible to AQP4+ NMOSD patients in Canada. Congratulations to all stakeholders for their tireless efforts to make this possible, including the pan-Canadian Pharmaceutical Alliance (pCPA), Alexion Canada and of course, the patients and advocates who supported this important initiative," said Sumaira Ahmed, Executive Director and Founder, The Sumaira Foundation. "The recent pCPA decision marks a key milestone in access to ravulizumab, offering patients with generalized myasthenia gravis a targeted, evidence-based biologic therapy. This agreement advances the treatment landscape and reflects a commitment to improving outcomes and quality of life for those affected by this chronic neuromuscular disorder," said Hans Katzberg, MD, MSc, FRCPC, FAAN, Professor of Medicine, University of Toronto. "Reaching this agreement is an important milestone in addressing the treatment gap for individuals with generalized myasthenia gravis. We look forward to seeing public drug programs list Ultomiris quickly and equitably across the country. It's critical that our health systems reflect fairness and urgency in responding to the needs of those with rare diseases like MG," said Dr. Homira Osman, Vice President of Research & Public Policy, Muscular Dystrophy Canada. "We would like to thank the pCPA for its partnership in recognizing the need for this important innovation for Canadians living with NMOSD and gMG. We look forward to our ongoing collaboration with provincial and territorial jurisdictions to finalize listing agreements and secure public reimbursement for patients and their caregivers," said Karen Heim, Vice President and General Manager of Alexion Canada. NMOSD NMOSD is a rare disease in which the immune system is inappropriately activated to target healthy tissues and cells in the CNS. 1 Approximately three-quarters of people with NMOSD are anti-AQP4 Ab+, meaning they produce antibodies that bind to a specific protein, aquaporin-4 (AQP4). 2-4 This binding can inappropriately activate the complement system, which is part of the immune system and is essential to the body's defence against infection, to destroy cells in the optic nerve, spinal cord and brain. 2-4 It most commonly affects women and begins in the mid-30s. Men and children may also develop NMOSD, but it is even more rare. 9-12 People with NMOSD may experience vision problems, intense pain, loss of bladder/bowel function, abnormal skin sensations (e.g., tingling, prickling or sensitivity to heat/cold) and impact on coordination and/or movement. 5 Most people living with NMOSD experience unpredictable relapses, also known as attacks. Each relapse can result in cumulative disability including vision loss, paralysis and sometimes premature death. 4,5 NMOSD is a distinct disease from other CNS diseases, including multiple sclerosis. 13 The journey to diagnosis can be long, with the disease sometimes misdiagnosed. 1 gMG gMG is a rare autoimmune disorder characterised by loss of muscle function and severe muscle weakness. 6 Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control. 14 This binding activates the complement system, causing the immune system to attack the NMJ leading to inflammation and a breakdown in communication between the brain and the muscles. 15 gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60. 16 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses such as impaired swallowing, choking, extreme fatigue and respiratory failure. 7,8 Ultomiris Ultomiris (ravulizumab), the longest-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Following a loading dose, Ultomiris is administered intravenously every eight weeks in adults, or every four or eight weeks in paediatric patients (based on body weight). Ultomiris is approved in the US, EU, Japan and other countries for the treatment of certain adults with paroxysmal nocturnal haemoglobinuria (PNH) and for certain children with PNH in the US and EU. Ultomiris is also approved in the US, EU, Japan and other countries for the treatment of certain adults and children with atypical haemolytic uraemic syndrome (aHUS). Additionally, Ultomiris is approved in the US, EU, Japan, China and other countries for the treatment of certain adults with generalised myasthenia gravis (gMG). Further, Ultomiris is approved in the US, EU, Japan and other countries for the treatment of certain adults with neuromyelitis optica spectrum disorder (NMOSD). Ultomiris is being assessed as a treatment for additional indications as part of a broad development programme. Alexion Alexion, AstraZeneca Rare Disease is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. For more information, please visit AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. References Jarius S, et al. The History of Neuromyelitis Optica. J Neuroinflammation. 2013;10:8. Hamid SHM, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088-2094. Yick LW, et al. Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice. Front. Immunol. 2018;9:1438. Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. Mutch K, et al. Life on Hold: The Experience of Living with Neuromyelitis Optica. Disabil Rehabil. 2014:36(13):1100-1107. Jung-Plath W, et al. Assessment of myasthenia gravis patients' quality of life. The Journal of Neurological and Neurosurgical Nursing. 2023;12(2):74-83. Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019. Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54. Bukhari W, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017:88(8):632-638. Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489. Drori T, et al. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmunity Reviews. 2014;13(4-5):531–533. Eaneff S, et al. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Multiple Sclerosis and Related Disorders. 2017;17:116–122. Mealy MA, et al. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. Int J MS care. 2019;21(3):129–134. Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981. Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024; 70(4):851-861. Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
Medical News Today
14-06-2025
- Health
- Medical News Today
Uplizna: Dosage, side effects, uses, interactions, cost, and more
The Food and Drug Administration (FDA) approves prescription drugs such as Uplizna to treat certain conditions. Uplizna may also be used off-label for other conditions. Off-label drug use is when an FDA-approved drug is prescribed for a purpose other than what it's approved for. Uplizna for NMOSD Uplizna is FDA approved to treat NMOSD in certain adults. Specifically, it's used in adults who test positive for an antibody (a type of immune system protein) called anti-aquaporin-4 (AQP4). NMOSD is a long-term autoimmune disorder that damages nerves in your eyes and spinal cord. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With NMOSD, your immune system mistakenly attacks nerve cells in your spinal cord and optic nerves. This stops these nerves from sending messages correctly. Symptoms of NMOSD can include: eye pain vision changes, such as dim or blurry vision pain, tingling, or numbness muscle spasms or weakness trouble walking problems with bladder or bowel control hiccups nausea and vomiting With NMOSD, you typically have periods where your symptoms flare up or worsen. These are called relapses or attacks. They may be followed by periods of remission, where your symptoms get better or go away. Uplizna helps to stop your immune system from attacking your optic nerves and spinal cord. This helps prevent the number and severity of relapses you may have. It may also lower your risk of needing hospital treatment for your symptoms. For this purpose, Uplizna may be prescribed on its own or with other drugs for NMOSD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna for IgG4-RD Uplizna is FDA approved to treat IgG4-RD in adults. Doctors may also call this condition IgG4-related sclerosing disease or IgG4-related systemic disease. IgG4-RD is a long-term autoimmune disorder that damages tissues and organs throughout your body. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue in your body. With IgG4-RD, your immune system mistakenly attacks many different tissues and organs in your body. This can cause widespread inflammation and damage to multiple organs. The organs and tissues most often affected by IgG4-RD include the pancreas, salivary glands, eyes, and tissues around the digestive organs. Other organs affected include the liver, kidneys, lungs, heart, and thyroid. Symptoms of IgG4-RD can vary, depending on what part of the body is affected. They can include: lumps, masses, or swellings dry mouth or eyes bulging eyes shortness of breath belly or back pain weight loss fatigue headaches With IgG4-RD, your symptoms may be ongoing, or they may flare up or get worse from time to time. You may also develop new symptoms if more parts of your body become affected. Flare-ups are also called relapses or attacks. Some people may also have periods of remission, where their symptoms get better or go away for a time. Uplizna helps to stop your immune system from attacking healthy tissues in your body. This helps prevent the number and severity of relapses you may have. For this purpose, Uplizna may be prescribed on its own or with other drugs for IgG4-RD. Examples of other drugs that doctors may prescribe with Uplizna include corticosteroids, such as methylprednisolone (Medrol) and prednisone. Uplizna and children Uplizna is not FDA-approved for any use in children. It's not known if the drug is safe or effective in children.
Hans India
08-05-2025
- Health
- Hans India
Rare neurological disorder treated by team of doctors
Visakhapatnam: A team of doctors at Care Hospitals successfully treated a 35-year-old woman Radha Rani, who was diagnosed with a rare neurological disorder Neuromyelitis Optica Spectrum Disorder (NMOSD) that caused severe spinal cord inflammation. She was completely bed-ridden when she was admitted to the hospital with complete loss of movement and sensation in her lower limbs. After treatment, the patient has been completely recovered, regaining mobility plus bladder control. Speaking on the occasion, MGV Aditya, senior neurologist, 'NMOSD with Longitudinally Extending Transverse Myelitis is an extremely rare condition with an estimated prevalence of 1 in 3 lakh individuals. Timely diagnosis and aggressive treatment are crucial.' The multidisciplinary team included AV Venugopal, senior consultant nephrologist and Srinivas, along with the critical care team, who worked together in the intensive care and management of the patient during her recovery journey. 'This case reinforces our commitment to delivering world-class, evidence-based treatment even in rare and complex cases. Radha Rani's full recovery is a testament to the skill, coordination, and dedication of our clinical team,' said Mayukh Chaudhuri, HCOO of the hospital.
